FibroBiologics Announces Filing of Patent Application for Generation of Functional Hematopoietic Organoids using Fibroblast Cell-Based Technology
12 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
06 sept. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
20 août 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the...
FibroBiologics Files 2024 Second Quarter Report
07 août 2024 18h52 HE
|
Fibrobiologics, Inc.
HOUSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of...
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
15 juil. 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, July 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
25 juin 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Set to Join Russell 2000® Index
13 juin 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, June 13, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
06 juin 2024 09h31 HE
|
Fibrobiologics, Inc.
HOUSTON, June 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Announces 2024 Annual Meeting of Stockholders
15 mai 2024 16h30 HE
|
Fibrobiologics, Inc.
HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the...
FibroBiologics Files 2024 First Quarter Report
14 mai 2024 17h24 HE
|
Fibrobiologics, Inc.
HOUSTON, May 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of...